| Drug General Information |
| Drug ID |
D0V8AC
|
| Former ID |
DIB020932
|
| Drug Name |
SD-208
|
| Synonyms |
SCI-208
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C17H10ClFN6
|
| InChI |
InChI=1S/C17H10ClFN6/c18-10-1-2-13(19)12(9-10)15-24-16-14(21-7-8-22-16)17(25-15)23-11-3-5-20-6-4-11/h1-9H,(H,20,22,23,24,25)
|
| InChIKey |
BERLXWPRSBJFHO-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
15325148, 22687180, 24899731, 29217656, 41381855, 57374546, 75033058, 99453617, 103534840, 104083354, 125767282, 134964519, 135697696, 137275822, 139720427, 152258471, 152344446, 160647306, 162248104, 163685748, 179694512, 186007040, 188376266, 204358201, 223704855, 224283133, 226738899, 241124675, 241376350, 244650250, 249565926, 249617808, 252157146, 252160103, 252480883
|
| Target and Pathway |
| Target(s) |
TGF-beta receptor type I |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Hippo signaling pathway
|
|
Adherens junction
|
|
Chagas disease (American trypanosomiasis)
|
|
Hepatitis B
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Chronic myeloid leukemia
|
|
PANTHER Pathway
|
TGF-beta signaling pathway
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
ALK1 signaling events
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
TGF-beta receptor signaling
|
|
Reactome
|
TGF-beta receptor signaling activates SMADs
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
SMAD2/3 Phosphorylation Motif Mutants in Cancer
|
|
SMAD2/3 MH2 Domain Mutants in Cancer
|
|
TGFBR2 Kinase Domain Mutants in Cancer
|
|
TGFBR1 KD Mutants in Cancer
|
|
TGFBR1 LBD Mutants in Cancer
|
|
WikiPathways
|
TGF Beta Signaling Pathway
|
|
p38 MAPK Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by TGF-beta Receptor Complex
|
|
Integrated Pancreatic Cancer Pathway
|
|
Integrated Breast Cancer Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8246). |
|---|
| REF 2 | Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1843-9. Epub 2007 Jan 24. |
|---|
